Ambar Protein Industries: Revenue Up, But Steep Profit Fall Sparks Margin Concerns
📉 The Financial Deep Dive
The Numbers:
Ambar Protein Industries' un-audited financial results for the third quarter ended December 31, 2025, revealed a divergence between top-line growth and bottom-line profitability. Revenue from operations increased by a notable 9.03% year-on-year to ₹121.92 Cr. Total income followed suit, rising 8.92% to ₹122.11 Cr. However, the cost of material consumed escalated sharply by 18.56% to ₹119.07 Cr, significantly eroding profitability. Consequently, Profit Before Tax (PBT) declined by 35.03% to ₹2.59 Cr, and Net Profit (PAT) saw a substantial decrease of 35.76% year-on-year to ₹1.81 Cr. Basic Earnings Per Share (EPS) fell by 35.64% to ₹3.16.
For the nine-month period ended December 31, 2025, revenue from operations grew by 20.44% to ₹353.86 Cr. Yet, the cost of material consumed surged by 25.19% to ₹336.46 Cr. This led to a 39.45% drop in PBT to ₹5.96 Cr and a 36.31% decrease in PAT to ₹4.56 Cr, with EPS falling 36.28% to ₹7.94.
The Quality:
The core issue highlighted by these results is margin compression. In Q3 FY26, the PBT margin contracted to 2.12% from 3.55% in Q3 FY25, and the PAT margin fell to 1.48% from 2.52%. The nine-month period showed a similar trend, with PBT margins narrowing from 3.34% to 1.68% and PAT margins from 2.43% to 1.29%. The substantial increase in material costs, outpacing revenue growth, is the primary driver behind this profitability squeeze.
The Grill:
This announcement exclusively contains financial results. No forward-looking management guidance, outlook, or concall commentary was provided. The financial statements underwent a limited review by Fenil P. Shah and Associates, Chartered Accountants, who reported no material misstatements. The absence of any forward-looking statements or management insights makes it difficult to gauge the company's strategy to combat rising input costs or its future growth prospects.